phosphonoacetic acid has been researched along with Carcinoma in 7 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 7.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 3.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "5-Fluorouracil (FUra) is a clinically useful antineoplastic agent." | 1.27 | Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. ( Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW, 1983) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Presant, CA | 1 |
| Ardalan, B | 2 |
| Multhauf, P | 1 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 1 |
| Carr, BI | 1 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Casper, ES | 1 |
| Vale, K | 1 |
| Williams, LJ | 1 |
| Martin, DS | 1 |
| Young, CW | 1 |
| Weiss, GR | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Kensler, TW | 2 |
| Mutter, G | 1 |
| Hankerson, JG | 1 |
| Reck, LJ | 2 |
| Harley, C | 1 |
| Han, N | 1 |
| Cysyk, RL | 1 |
| Johnson, RK | 2 |
| Jayaram, HN | 1 |
| Cooney, DA | 2 |
| Osieka, R | 1 |
| Houchens, DP | 1 |
| Goldin, A | 1 |
| Chiou, JF | 1 |
| Li, JK | 1 |
| Cheng, YC | 1 |
7 other studies available for phosphonoacetic acid and Carcinoma
| Article | Year |
|---|---|
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Blood Cell Count; Carcinoma; Drug Admin | 1983 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Topics: Amides; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma; Cell Line; Dose-Response | 1981 |
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1981 |
Chemotherapy of human colon cancer xenografts in athymic nude mice.
Topics: Acridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma | 1977 |
Demonstration of a stimulatory protein for virus-specified DNA polymerase in phorbol ester-treated Epstein-Barr virus-carrying cells.
Topics: Carcinoma; Cell Line; DNA-Directed DNA Polymerase; Enzyme Activation; Foscarnet; Herpesvirus 4, Huma | 1985 |